Nav: Home

SWOG cancer research network study opens window into immune microenviroment

April 09, 2019

The first comprehensive study of immune cell types in pre- and post-chemotherapy cancer tissues points up a host of targets for new or existing cancer drugs that could improve patients' sensitivity to both chemotherapy and immunotherapy.

Results from the SWOG Cancer Research Network study appear in the latest issue of the Journal for ImmunoTherapy of Cancer. The results provide a detailed look at the immune cells found in breast cancer tumors before and after chemotherapy - providing scientists a rare window into the immune microenviroment and how it's affected by cancer drugs.

"When we better understand the types and functions of immune cells found in cancer tissue, and the effects of drugs on those cells, the closer we get to finding effective treatments," said Lajos Pusztai, MD, chair of SWOG's breast cancer committee and senior author of the journal article. "With this study, we get a unique look at the tumor immune microenvironment - and identify potential therapeutic targets that can be tested in the clinic."

SWOG is a publicly funded cancer research network that has run over 1,400 National Cancer Institute funded trials since 1956. A major benefit of that longevity: the accumulation of over 800,000 blood, tissue, and other specimens in SWOG's biobank. Pusztai, of Yale Cancer Center, and his SWOG team located 60 paired tissue samples in the bank that were taken for S0800, a randomized trial that compared two pre-surgical chemotherapy treatments for patients with HER2-negative, locally advanced, or inflammatory breast cancers.

The team used this subset of paired pre- and post-treatment tissues to accomplish three goals: determine the presence of the cancer-attacking immune cells known as tumor infiltrating lymphocytes (TILs); measure the expression of the immune-suppressing protein PD-L1, and the expression of 750 other immune-related genes that can show immune cell activity in pre- and post-treatment tissues.

To do this work, Pusztai and his team used three methods. These included a pathologist counting TILs under a microscope, and laboratory scientists using an assay to determine PD-L1 expression. In addition, article lead author Xiaotong Li, a computational biologist at Yale, used another assay, the NanoString PanCancer IO 360 Gene Expression Panel, to measure the expression of 750 immune-related genes with the help of a team of from NanoString.

Here are the results:
  • The team found higher counts of cancer-fighting TILs in the pre-treatment tissue samples of breast cancer patients who saw their cancer disappear after chemotherapy, a phenomenon known as pathologic complete response, or pCR. The TIL counts in post-treatment tissues were significantly lower when compared with pre-treatment tissues, suggesting that immune cells are killed by chemotherapy agents.

  • Researchers did not find any significant changes to PD-L1 protein expression in any of the comparison groups - between patients whose tumors disappeared to those whose tumors merely shrunk, or between pre- and post-treatment tissue samples.

  • The team found 24 immune genes more highly expressed in patients who saw a complete response to chemotherapy, including genes that control the cell-killing enzymes granzyme and granulysin and the cytokines CCL21 and CCL19, proteins that activate cancer-fighting T cells. The IL7R gene that controls the production of T calls is also more active in patients who saw their cancer disappear after chemotherapy. This suggests that these molecules play an important role in activating and attracting immune cells - and any drugs that increase their expression or activity could improve treatment response.

  • The team found that the proteins CXCL1, CXCL2, CXCL3, and CCL20, and the IL6 gene, were more highly expressed in patients who did not get a complete response to chemotherapy. This suggests that drugs that decrease the presence of these proteins and the activity of this gene could improve treatment response.
"Our findings revealed several highly actionable immune targets that can get tested in the clinic," Pusztai said. And, in fact, he is already doing so. Pusztai is leading S1418, a SWOG breast cancer trial testing the immunotherapy drug pembrolizumab, which targets PD-1, to find out if it will improve survival of triple negative breast cancer patients who have PD-L1 expression in their cancer after pre-operative chemotherapy.
-end-
This SWOG study was funded by the National Institutes of Health through National Cancer Institute grant awards CA180888, CA180819, CA180826, CA180858, and CA180801 and in part by Genentech (Roche), Abraxis BioScience (Celgene), HelomixTM, Nanostring Technologies, Inc., a Susan G. Komen Leadership Award, and grants from the Breast Cancer Research Foundation.

Along with Pusztai and Li of Yale Cancer Center, the SWOG team includes Sarah Warren, PhD, of NanoString Technologies; Vasiliki Pelekanou, MD, PhD, of Yale School of Medicine; Alessandra Cesano, MD, PhD, of NanoString Technologies; Mingdong Liu, PhD, of NanoString Technologies; Patrick Danaher, PhD, of NanoString Technologies; Nathan Elliott, PhD, of NanoString Technologies; Zeina A. Nahleh, MD, of Cleveland Clinic Florida; Daniel F. Hayes, MD, of University of Michigan Rogel Cancer Center; Gabriel Hortobagyi, MD, of University of Texas MD Anderson Cancer Center; William E. Barlow, PhD, of the SWOG Statistics and Data Management Center at Fred Hutchinson Cancer Research Center; and Christos Hatzis, PhD, of Yale Cancer Center.

SWOG Cancer Research Network is part of the National Cancer Institute's National Clinical Trials Network and the NCI Community Oncology Research Program, and is part of the oldest and largest publicly-funded cancer research network in the nation. SWOG has nearly 12,000 members in 46 states and six foreign countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at swog.org.

SWOG

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.